ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
66 785,64
-0,44%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Karuna Therapeutics Inc (KRTX)

  7. Karuna Therapeutics Inc (KRTX) Actualités

KRTX

Karuna Therapeutics (KRTX)

Karuna Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KRTX
DateHeureSourceTitreSymboleSociété
11/03/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
08/03/202423h01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
01/03/202412h02Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRTXKaruna Therapeutics Inc
01/03/202412h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRTXKaruna Therapeutics Inc
22/02/202412h39Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KRTXKaruna Therapeutics Inc
22/02/202412h30Business WireKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateNASDAQ:KRTXKaruna Therapeutics Inc
14/02/202416h04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KRTXKaruna Therapeutics Inc
05/02/202422h12Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:KRTXKaruna Therapeutics Inc
22/01/202412h05Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:KRTXKaruna Therapeutics Inc
08/01/202416h06PR Newswire (US)Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law FirmNASDAQ:KRTXKaruna Therapeutics Inc
22/12/202321h30PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.NASDAQ:KRTXKaruna Therapeutics Inc
22/12/202317h15Dow Jones NewsTrending: Bristol Myers to Buy Karuna Therapeutics for $14 BillionNASDAQ:KRTXKaruna Therapeutics Inc
22/12/202313h05Business WireBristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna TherapeuticsNASDAQ:KRTXKaruna Therapeutics Inc
15/12/202300h30Business WireKaruna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in SchizophreniaNASDAQ:KRTXKaruna Therapeutics Inc
29/11/202316h17Business WirePureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of SchizophreniaNASDAQ:KRTXKaruna Therapeutics Inc
29/11/202313h13Dow Jones NewsKaruna Therapeutics Gets FDA Acceptance for KarXT NDANASDAQ:KRTXKaruna Therapeutics Inc
29/11/202312h30Business WireKaruna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of SchizophreniaNASDAQ:KRTXKaruna Therapeutics Inc
16/11/202322h01Business WireKaruna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in SchizophreniaNASDAQ:KRTXKaruna Therapeutics Inc
02/11/202311h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRTXKaruna Therapeutics Inc
02/11/202311h30Business WireKaruna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesNASDAQ:KRTXKaruna Therapeutics Inc
01/11/202311h45Business WireKaruna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute CongressNASDAQ:KRTXKaruna Therapeutics Inc
01/11/202311h30Business WireKaruna Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:KRTXKaruna Therapeutics Inc
19/10/202312h30Business WireKaruna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023NASDAQ:KRTXKaruna Therapeutics Inc
04/10/202312h30Business WireKaruna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) CongressNASDAQ:KRTXKaruna Therapeutics Inc
03/10/202323h15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
28/09/202312h30Business WireKaruna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of SchizophreniaNASDAQ:KRTXKaruna Therapeutics Inc
03/08/202312h32Business WireKaruna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business UpdatesNASDAQ:KRTXKaruna Therapeutics Inc
03/08/202312h30Business WireKaruna Therapeutics Announces Leadership AppointmentsNASDAQ:KRTXKaruna Therapeutics Inc
20/07/202312h30Business WireKaruna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023NASDAQ:KRTXKaruna Therapeutics Inc
22/06/202322h19Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KRTXKaruna Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KRTX

Dernières Valeurs Consultées

BIT
UC72PU
Unicredit Bank
LBNK
OPTUSDT
Optimus
NASDAQ
FANZX
Franklin Moderate Alloca...
BITMOT
965237
Romania Tf 7,625% Ge53 Usd
EU
D489T
D489T
LSE
03GW
F & C 41/4%
TSXV
ECR
Cartier Resources
LSE
IWVL
Ish W Factor Va
COIN
EDCNUSD
EarnDefiCoin
BIT
UC24CK
Unicredit Bank
TIDE
E2CBTC
USOTC
PGXPF
Pelangio Exploration (PK)
COIN
KPCCBTC
KOLOOP BASIC
COIN
POPPEUR
BOV
W1BO34M
Weibo
NASDAQ
RBPAA
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés